Cantor Fitzgerald Predicts TVTX FY2025 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Travere Therapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn ($1.13) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.93) per share.

A number of other research analysts have also recently issued reports on the company. Guggenheim lifted their price objective on Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Barclays upped their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Bank of America raised their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright lifted their target price on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, January 15th. Finally, Wells Fargo & Company raised Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $9.00 to $27.00 in a report on Monday, October 21st. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Travere Therapeutics has an average rating of “Moderate Buy” and an average target price of $24.00.

Travere Therapeutics Stock Up 5.9 %

TVTX stock opened at $19.46 on Wednesday. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The firm has a 50 day moving average price of $18.21 and a 200-day moving average price of $14.72. Travere Therapeutics has a 52-week low of $5.12 and a 52-week high of $20.33.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.01. The company had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. Travere Therapeutics’s quarterly revenue was up 69.6% compared to the same quarter last year. During the same period last year, the business earned ($1.17) EPS.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently made changes to their positions in the business. CWM LLC grew its position in shares of Travere Therapeutics by 158.5% during the third quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after purchasing an additional 3,065 shares in the last quarter. DRW Securities LLC purchased a new position in Travere Therapeutics during the 2nd quarter valued at approximately $95,000. Quarry LP bought a new stake in Travere Therapeutics in the 3rd quarter worth approximately $105,000. Forefront Analytics LLC raised its holdings in shares of Travere Therapeutics by 10.2% during the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after acquiring an additional 1,237 shares in the last quarter. Finally, Sei Investments Co. purchased a new stake in Travere Therapeutics during the second quarter valued at $117,000.

Insider Activity

In other news, CAO Sandra Calvin sold 15,000 shares of the stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the sale, the chief accounting officer now directly owns 54,927 shares of the company’s stock, valued at $945,842.94. This represents a 21.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jula Inrig sold 2,066 shares of Travere Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $19.10, for a total transaction of $39,460.60. Following the transaction, the insider now owns 59,883 shares in the company, valued at approximately $1,143,765.30. This trade represents a 3.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,596 shares of company stock valued at $527,262 in the last 90 days. Company insiders own 4.06% of the company’s stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.